Spread the love

The 1989 Nobel prize winner in Physiology/Medicine Prof. Varmus Harold ESomwar R and others from High Throughput Screening Core Facility, and Organic Synthesis Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; and US National Cancer Institute, USA has published a research paper in the 27 September 2011 issue of Proc Natl Acad Sci U S A. (I.F: >10) stating that “Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.”  

Based on this this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Molecular therapy for Human cancer: E3 ubiquitin-protein ligase COP1 inhibits tumor cell proliferation via down regulation of  Superoxide dismutase 1 (SOD1).  This result  suggests that COP1, by decreasing the expression of its target gene, it may decrease the expression of SOD1. Thereby, it may increase the levels of Superoxide anions in cancer cells, which in turn may increase the expression of a number of tumor suppressor genes.  Thus, pharmacological formulations encompassing COP1  or its activators” may be used to treat human cancers.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

To citeBoominathan, Molecular therapy for Human cancer: E3 ubiquitin-protein ligase COP1 inhibits tumor cell proliferation via down regulation of  Superoxide dismutase 1 (SOD1), 04/October/2014, 21.22,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love